$DJI 0.59% NDX 0.99% SPX 0.49% VIX 9.04% News *
Sun, Sep 22 1:54am

CELG $99.37 0.42 (0.42%)
Celgene Corp | NASDAQ

CELG Profile

Market Cap 69.75 Billion
CELG Description

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.

Visit Website

CELG Earnings

EPS 2.22 P/E Ratio 17.70
Previous Thu, Apr 25, 2019
Latest Tue, Jul 30, 2019 (54 days ago) +6.86%

CELG Dividend

Yield --
Ex-Date --
Pay Date --
History --

CELG Charts

1 Year
Dec 24, 2018

Symbol Price Day Δ YTD Δ
CELG $99.37 0.42% 49.11%


Symbol Surfing

How can we make Symbol Surfing better?


Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

©2019 Symbol Surfing All Rights Reserved.

Cookies Policy | Terms Of Service | Privacy Policy